<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04324814</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-001AUS</org_study_id>
    <nct_id>NCT04324814</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1701 in Subjects With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atridia Pty Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atridia Pty Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dose-escalation and dose-expansion Phase 1 trial to evaluate the safety and
      tolerability of SHR-1701 in subjects with advanced solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a two-part, open-label, multicenter, non-randomized, dose escalation, Phase 1 study
      of repeated doses of SHR-1701 in subjects with advanced solid tumors who have failed current
      standard anti-tumor therapies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Dose escalation is designed according to a modified 3+3 scheme, in which 3 to 6 subjects will be enrolled in each dose group. Four dose levels of SHR-1701 are planned. after dose esclation completed, selected cohort(s) will be expanded.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
    <description>Number of subjects with adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory results</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
    <description>Number of subjects with laboratory tests findings of potential clinical importance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
    <description>Incidence of vital sign abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Electrocardiogram</measure>
    <time_frame>Screening up to study completion, an average of 1 year</time_frame>
    <description>Number of subjects with clinically significant abnormal ECG QT Interval</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - Cmax</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of SHR-1701</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - AUC∞</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity of SHR-1701</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - Tmax</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Time to Cmax of SHR-1701</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - CL/F</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Apparent clearance of SHR-1701</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - Vz/F</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Apparent volume of distribution during terminal phase of SHR-1701</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic - t1/2</measure>
    <time_frame>Pre-dose, 10min(±2min), 1h(±5min), 2h(±5min), 6h(±10min) Post-dose on Cycle1 Day 1, pre-dose on Day 2, 3, 4, 8, 15</time_frame>
    <description>Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics- ADA</measure>
    <time_frame>Pre-dose on Day1 of cycle 2,3,4,5,7,9,13,17</time_frame>
    <description>Anti-drug antibody of PD-L1</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 of each cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single dose of SHR-1701 at Dose level 1 on Day 1 and Day 15 of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>Anti-PD-L1/TGFβ fusion protein</description>
    <arm_group_label>Dose level 1</arm_group_label>
    <arm_group_label>Dose level 2</arm_group_label>
    <arm_group_label>Dose level 3</arm_group_label>
    <arm_group_label>Dose level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed (histologically or cytologically) with solid tumors

          -  ECOG Performance Status of 0 or 1 at both the screening and baseline visits

          -  Life expectancy ≥12 weeks

          -  Adequate laboratory parameters

          -  Willing and able to comply with clinic visits and study-related procedures

          -  Provide signed informed consent

        Exclusion Criteria:

          -  Known history of hypersensitivity to the study drug

          -  Prior malignancy active within the previous 2 years

          -  Any investigational or concurrent cancer therapy

          -  History of immunodeficiency including seropositivity

          -  Systemic antibiotics treatment for ≥ 7 days before the first dose

          -  A known history of allogeneic organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kathy You, PhD</last_name>
    <phone>+61 02 9299 0433</phone>
    <email>kathyyou@atridia.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mengliu Di, Pharm.D</last_name>
    <phone>+8613057380712</phone>
    <email>dimengliu@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icon Cancer Care Centre</name>
      <address>
        <city>South Brisbane</city>
        <state>New South Wales</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meniawy Tarek, Dr.</last_name>
      <phone>1300 546 327 (1300Linear)</phone>
      <email>enquiries@linear.org.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2020</study_first_posted>
  <last_update_submitted>April 10, 2020</last_update_submitted>
  <last_update_submitted_qc>April 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

